|
|
Taiwan Academic Institutional Repository >
Browse by Author
|
"boku n"
Showing items 26-35 of 40 (4 Page(s) Totally)
<< < 1 2 3 4 > >>
View [10|25|50] records per page
| 國家衛生研究院 |
2019-02 |
Evaluation of efficacy of nivolumab by baseline factors from ATTRACTION-2
|
Kang, YK;Satoh, T;Chao, Y;Kato, K;Chung, HC;Chen, JS;Muro, K;Kang, WK;Yoshikawa, T;Oh, SC;Tamura, T;Lee, KW;Morita, S;Chen, LT;Boku, N |
| 國立成功大學 |
2019 |
Safety and efficacy of nivolumab in combination with s-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: Interim results of a randomized, phase II trial (a
|
Boku, N.;Ryu, M.-H.;Kato, Kato K.;Chung, H.C.;Minashi, K.;Lee, K.-W.;Cho, H.;Kang, W.K.;Komatsu, Y.;Tsuda, M.;Yamaguchi, K.;Hara, Hara H.;Fumita, S.;Azuma, M.;Chen, L.-T.;Kang, Y.-K. |
| 國立成功大學 |
2019 |
A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy re
|
Kato, Kato K.;Satoh, T.;Muro, K.;Yoshikawa, T.;Tamura, Tamura T.;Hamamoto, Y.;Chin, K.;Minashi, K.;Tsuda, M.;Yamaguchi, K.;Machida, N.;Esaki, T.;Goto, M.;Komatsu, Y.;Nakajima, T.E.;Sugimoto, N.;Yoshida, K.;Oki, E.;Nishina, T.;Tsuji, A.;Fujii, H.;Kunieda, Kunieda K.;Saitoh, Saitoh S.;Omuro, Y.;Azuma, M.;Iwamoto, Y.;Taku, K.;Fushida, S.;Chen, L.-T.;Kang, Y.-K.;Boku, N. |
| 國立成功大學 |
2019 |
Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design
|
Moehler, Moehler M.;Ryu, M.-H.;Dvorkin, M.;Lee, K.-W.;Coşkun, H.Ş.;Wong, R.;Chung, H.C.;Poltoratsky, A.;Tsuji, A.;Yen, C.J.;Muntean, A.S.;Le, Sourd S.;Vaccaro, G.M.;Overton, L.;Boku, N.;Wainberg, Z.A.;Patel, M.;Sharma, M.;Xiong, H.;Conti, I.;Taieb, J.;Bang, Y.-J. |
| 國家衛生研究院 |
2018-12-19 |
Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: Interim results of a randomized, phase 2 trial (AT
|
Boku, N;Ryu, MH;Kato, K;Chung, HC;Minashi, K;Lee, KW;Cho, H;Kang, WK;Komatsu, Y;Tsuda, M;Yamaguchi, K;Hara, H;Fumita, S;Azuma, M;Chen, LT;Kang, YK |
| 國家衛生研究院 |
2018-12-01 |
A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens
|
Kato, K;Satoh, T;Muro, K;Yoshikawa, T;Tamura, T;Hamamoto, Y;Chin, K;Minashi, K;Tsuda, M;Yamaguchi, K;Machida, N;Esaki, T;Goto, M;Komatsu, Y;Nakajima, TE;Sugimoto, N;Yoshida, K;Oki, E;Nishina, T;Tsuji, A;Fujii, H;Kunieda, K;Saitoh, S;Omuro, Y;Azuma, M;Iwamoto, Y;Taku, K;Fushida, S;Chen, LT;Kang, YK;Boku, N |
| 國家衛生研究院 |
2018-09 |
Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials
|
Haag, GM;Chen, LT;Kang, YK;Satoh, T;Kato, K;Chung, HC;Kang, WK;Chao, Y;Chen, JS;Ott, PA;Le, DT;Zhao, H;Exposito, MJJ;Janjigian, YY;Boku, N;Chau, I |
| 國家衛生研究院 |
2018-05 |
Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials
|
Chau, I;Chen, LT;Kang, YK;Satoh, T;Kato, K;Chung, HC;Kang, WK;Chao, Y;Chen, JS;Ott, PA;Le, DT;Zhao, HY;Jimenez-Exposito, MJ;Janjigian, YY;Boku, N |
| 國家衛生研究院 |
2018-02 |
Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials
|
Chau, I;Chen, LT;Kang, YK;Satoh, T;Kato, K;Chung, HC;Kang, WK;Chao, Y;Chen, JS;Ott, PA;Le, DT;Zhao, H;Jimenez-Exposito, MJ;Janjigian, YY;Boku, N |
| 國家衛生研究院 |
2017-12 |
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial
|
Kang, YK;Boku, N;Satoh, T;Ryu, MH;Chao, Y;Kato, K;Chung, HC;Chen, JS;Muro, K;Kang, WK;Yeh, KH;Yoshikawa, T;Oh, SC;Bai, LY;Tamura, T;Lee, KW;Hamamoto, Y;Kim, JG;Chin, K;Oh, DY;Minashi, K;Cho, JY;Tsuda, M;Chen, LT |
Showing items 26-35 of 40 (4 Page(s) Totally)
<< < 1 2 3 4 > >>
View [10|25|50] records per page
|
